<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-type="olc" bill-stage="Introduced-in-Senate" dms-id="A1" public-private="public" slc-id="S1-TAM25324-019-T9-X1S"><metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>119 S932 IS: Give Kids a Chance Act of 2025</dc:title>
<dc:publisher>U.S. Senate</dc:publisher>
<dc:date>2025-03-11</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">II</distribution-code><congress>119th CONGRESS</congress><session>1st Session</session><legis-num>S. 932</legis-num><current-chamber>IN THE SENATE OF THE UNITED STATES</current-chamber><action><action-date date="20250311" legis-day="20250310">March 11 (legislative day, March 10), 2025</action-date><action-desc><sponsor name-id="S419">Mr. Mullin</sponsor> (for himself and <cosponsor name-id="S330">Mr. Bennet</cosponsor>) introduced the following bill; which was read twice and referred to the <committee-name committee-id="SSHR00">Committee on Health, Education, Labor, and Pensions</committee-name></action-desc></action><legis-type>A BILL</legis-type><official-title>To amend the Federal Food, Drug, and Cosmetic Act with respect to molecularly targeted pediatric cancer investigations, and for other purposes.</official-title></form><legis-body style="OLC"><section id="HFAB52CF59F174712B88194D7DE448042" section-type="section-one"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>Give Kids a Chance Act of 2025</short-title></quote>. </text></section><section id="H9E1778E7CEA847D992D4937B13141F33"><enum>2.</enum><header>Research into pediatric uses of drugs; additional authorities of Food and Drug Administration regarding molecularly targeted cancer drugs</header><subsection id="H6377E17EB6EC4AB7A6F35E8F69AB989A"><enum>(a)</enum><header>In general</header><paragraph id="H3F684FA080D8453FAD138B83E394A94F"><enum>(1)</enum><header>Additional active ingredient for application drug; limitation regarding novel-combination application drug</header><text>Section 505B(a)(3) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355c">21 U.S.C. 355c(a)(3)</external-xref>) is amended—</text><subparagraph id="H1AA0DD8DC86A402A9D617D3F159F49C0"><enum>(A)</enum><text>by redesignating subparagraphs (B) and (C) as subparagraphs (C) and (D), respectively; and</text></subparagraph><subparagraph id="H2E182568BE6B418EAA77A85A11391BF9"><enum>(B)</enum><text>by striking subparagraph (A) and inserting the following:</text><quoted-block style="OLC" id="H65E7EAA4F1D2470AA0E2084A5073B8C4"><subparagraph id="HC10A2DF8C7D24C55B856AA17A23C3398"><enum>(A)</enum><header>In general</header><text>For purposes of paragraph (1)(B), the investigation described in this paragraph is a molecularly targeted pediatric cancer investigation of—</text><clause id="H3D131A85C59E451A9574380013423FC0"><enum>(i)</enum><text>the drug or biological product for which the application referred to in such paragraph is submitted; or</text></clause><clause id="HF0D47D4765014DEE93F90F791A034BA4"><enum>(ii)</enum><text>such drug or biological product used in combination with—</text><subclause id="HE607491BCE304D6180ADB2A672582D61"><enum>(I)</enum><text display-inline="yes-display-inline">an active ingredient of a drug or biological product—</text><item id="HD913C1014143440E8242661AA7F49809"><enum>(aa)</enum><text>for which an approved application under section 505(j) under this Act or under section 351(k) of the Public Health Service Act is in effect; and</text></item><item id="HB47B9C92026D4BC58E04AA3E241E4C84"><enum>(bb)</enum><text display-inline="yes-display-inline">that is determined by the Secretary, after consultation with the applicant, to be part of the standard of care for treating a pediatric cancer; or</text></item></subclause><subclause id="H8CFFCC1E31914F9EBC59A52B0DEB0A96"><enum>(II)</enum><text display-inline="yes-display-inline">an active ingredient of a drug or biological product—</text><item id="H6BBE7B673AE341268CE07B3DE0A4E029"><enum>(aa)</enum><text>for which an approved application under section 505(b) of this Act or section 351(a) of the Public Health Service Act to treat an adult cancer is in effect and is held by the same person submitting the application under paragraph (1)(B); and</text></item><item id="H05F0B8849D6749BA8C035F548207ED5C"><enum>(bb)</enum><text>that is directed at a molecular target that the Secretary determines to be substantially relevant to the growth or progression of a pediatric cancer. </text></item></subclause></clause></subparagraph><subparagraph id="H051DA1684F5642A2A9CC14D853927836"><enum>(B)</enum><header>Additional requirements</header><clause id="HBA610156E5074D30BFD195BB0012E72B"><enum>(i)</enum><header>Design of investigation</header><text display-inline="yes-display-inline">A molecularly targeted pediatric cancer investigation referred to in subparagraph (A) shall be designed to yield clinically meaningful pediatric study data that is gathered using appropriate formulations for each age group for which the study is required, regarding dosing, safety, and preliminary efficacy to inform potential pediatric labeling.</text></clause><clause id="HB6AE104226FF4CE2BA514DC75EDA1DBF"><enum>(ii)</enum><header>Limitation</header><text>An investigation described in subparagraph (A)(ii) may be required only if the drug or biological product for which the application referred to in paragraph (1)(B) contains either—</text><subclause id="H715A162ADD1C4E93A0CF9CAC2A666765"><enum>(I)</enum><text>a single new active ingredient; or </text></subclause><subclause id="H8F77059315634E66824B70EC00C2974C"><enum>(II)</enum><text>more than one active ingredient, if an application for the combination of active ingredients has not previously been approved but each active ingredient is in a drug product that has been previously approved to treat an adult cancer. </text></subclause></clause><clause id="HDBC64E3A8AD64D1982C98B10C72F7AAC"><enum>(iii)</enum><header>Results of already-completed preclinical studies of application drug</header><text>With respect to an investigation required pursuant to paragraph (1)(B), the Secretary may require the results of any completed preclinical studies relevant to the initial pediatric study plan be submitted to the Secretary at the same time that the initial pediatric study plan required under subsection (e)(1) is submitted. </text></clause><clause id="H5C6952D5C64C4976BC1988E651AF482C"><enum>(iv)</enum><header>Rule of construction regarding inactive ingredients</header><text>With respect to a combination of active ingredients referred to in subparagraph (A)(ii), such subparagraph shall not be construed as addressing the use of inactive ingredients with such combination.</text></clause></subparagraph><after-quoted-block>.</after-quoted-block></quoted-block></subparagraph></paragraph><paragraph id="H0551FE7AF4BB4DB1884C33CFAB41CD6D"><enum>(2)</enum><header>Determination of applicable requirements</header><text display-inline="yes-display-inline">Section 505B(e)(1) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355c">21 U.S.C. 355c(e)(1)</external-xref>) is amended by adding at the end the following: <quote>The Secretary shall determine whether subparagraph (A) or (B) of subsection (a)(1) applies with respect to an application before the date on which the applicant is required to submit the initial pediatric study plan under paragraph (2)(A).</quote>.</text></paragraph><paragraph id="H17E7B2FC5AE04A618C3C16A28CF775AA"><enum>(3)</enum><header>Clarifying applicability</header><text display-inline="yes-display-inline"><italic></italic>Section 505B(a)(1) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355c">21 U.S.C. 355c(a)(1)</external-xref>) is amended by adding at the end the following:</text><quoted-block style="OLC" id="H1E473882D14544F9810BA50BA068ABDB" display-inline="no-display-inline"><subparagraph id="H9A0ED9BF83E1490B81CBE6C4E63A0015"><enum>(C)</enum><header>Rule of construction</header><text display-inline="yes-display-inline">No application that is subject to the requirements of subparagraph (B) shall be subject to the requirements of subparagraph (A), and no application (or supplement to an application) that is subject to the requirements of subparagraph (A) shall be subject to the requirements of subparagraph (B).</text></subparagraph><after-quoted-block>.</after-quoted-block></quoted-block></paragraph><paragraph id="H09698095BC204D578F783880E7CEEA3B"><enum>(4)</enum><header>Conforming amendments</header><text>Section 505B(a) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355c">21 U.S.C. 355c(a)</external-xref>) is amended—</text><subparagraph id="H353C9341656F4199ADB56CFBCF4A44AA"><enum>(A)</enum><text>in paragraph (3)(C), as redesignated by paragraph (1)(A) of this subsection, by striking <quote>investigations described in this paragraph</quote> and inserting <quote>investigations referred to in subparagraph (A)</quote>; and</text></subparagraph><subparagraph id="HA7BDFFA1B7214001AC8F9E84B099A79F"><enum>(B)</enum><text>in paragraph (3)(D), as redesignated by paragraph (1)(A) of this subsection, by striking <quote>the assessments under paragraph (2)(B)</quote> and inserting <quote>the assessments required under paragraph (1)(A)</quote>.</text></subparagraph></paragraph></subsection><subsection id="H1C79C62C929F40BBA4390C5FA745AE7D"><enum>(b)</enum><header>Guidance</header><text display-inline="yes-display-inline">The Secretary of Health and Human Services, acting through the Commissioner of Food and Drugs, shall—</text><paragraph id="H666D40AB77AA489BAD1B925630D2C1BD"><enum>(1)</enum><text>not later than 12 months after the date of enactment of this Act, issue draft guidance on the implementation of the amendments made by subsection (a); and</text></paragraph><paragraph id="H1E063AF765284AB4A455163299D1DC5B"><enum>(2)</enum><text>not later than 12 months after closing the comment period on such draft guidance, finalize such guidance.</text></paragraph></subsection><subsection id="H16BE4DC46693401E80DE43DA724D224C" commented="no"><enum>(c)</enum><header>Applicability</header><text display-inline="yes-display-inline">The amendments made by this section apply with respect to any application under section 505(b) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355">21 U.S.C. 355(b)</external-xref>) and any application under section 351(a) of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/262">42 U.S.C. 262(a)</external-xref>), that is submitted on or after the date that is 3 years after the date of enactment of this Act.</text></subsection><subsection id="HEA7163ACB0E84C2094D313EFD8A97B1E"><enum>(d)</enum><header>Reports to Congress</header><paragraph id="HC993954DCE7F48B9A2BE2617B0BCBFD7"><enum>(1)</enum><header>Secretary of Health and Human Services</header><text display-inline="yes-display-inline">Not later than 6 years after the date of enactment of this Act, the Secretary of Health and Human Services shall submit to the Committee on Energy and Commerce of the House of Representatives and the Committee on Health, Education, Labor, and Pensions of the Senate a report on the Secretary’s efforts, in coordination with industry, to ensure implementation of the amendments made by subsection (a).</text></paragraph><paragraph id="HC70D07684ADC4EB2AEC6F21CCCF135FC"><enum>(2)</enum><header>GAO study and report</header><subparagraph id="H703645629C3449D5B1D58A9576EE0961"><enum>(A)</enum><header>Study</header><text>Not later than 8 years after the date of enactment of this Act, the Comptroller General of the United States shall conduct a study of the effectiveness of requiring assessments and investigations described in section 505B of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355c">21 U.S.C. 355c</external-xref>), as amended by subsection (a), in the development of drugs and biological products for pediatric cancer indications, including consideration of any benefits to, or burdens on, pediatric cancer drug development. </text></subparagraph><subparagraph id="H4133D8AD3E61451DABDAE8C58141B2F3"><enum>(B)</enum><header>Findings</header><text>Not later than 10 years after the date of enactment of this Act, the Comptroller General shall submit to the Committee on Energy and Commerce of the House of Representatives and the Committee on Health, Education, Labor, and Pensions of the Senate a report containing the findings of the study conducted under subparagraph (A).</text></subparagraph></paragraph></subsection></section><section id="H211AF97D73D84607B68E8C81353D573E"><enum>3.</enum><header>Extension of authority to issue priority review vouchers to encourage treatments for rare pediatric diseases</header><subsection id="H9C5C1DF5E3B741CCBB4E015CAD8AC892"><enum>(a)</enum><header>Extension</header><text display-inline="yes-display-inline">Section 529(b)(5) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/360ff">21 U.S.C. 360ff(b)(5)</external-xref>) is amended by striking <quote>December 20, 2024, unless</quote> and all that follows through the period at the end and inserting <quote>September 30, 2029.</quote>.</text></subsection><subsection id="id0f4ce340136341cfa5c3d549ba3ef223"><enum>(b)</enum><header>User fee payment</header><text>Subsection 529(c)(4) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/360ff">21 U.S.C. 360ff(c)(4)</external-xref>) is amended by striking subparagraph (A) and inserting the following:</text><quoted-block style="OLC" display-inline="no-display-inline" id="idBF00355F840043799F6C45530B47357E"><subparagraph id="id26cb2277820b4219ae5b2fc1bb7f9e58"><enum>(A)</enum><header>In general</header><text>The priority review user fee required by this subsection shall be due upon the submission of a human drug application under section 505(b)(1) or section 351(a) of the Public Health Service Act for which the priority review voucher is used. All other user fees associated with the human drug application shall be due as required by the Secretary or under applicable law.</text></subparagraph><after-quoted-block>.</after-quoted-block></quoted-block></subsection><subsection id="H5F5EF97781454536B86A0FCEB31BB541"><enum>(c)</enum><header>GAO report on effectiveness of rare pediatric disease priority voucher awards in incentivizing rare pediatric disease drug development</header><paragraph id="HBD9D8FF37439424796DD0EC31C839648"><enum>(1)</enum><header>GAO study</header><subparagraph id="HCE9BEBDF14F643619254AD5DC5CB7E1D"><enum>(A)</enum><header>Study</header><text display-inline="yes-display-inline">The Comptroller General of the United States shall conduct a study of the effectiveness of awarding rare pediatric disease priority vouchers under section 529 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/360ff">21 U.S.C. 360ff</external-xref>), as amended by subsection (a), in the development of human drug products that treat or prevent rare pediatric diseases (as defined in such section 529).</text></subparagraph><subparagraph id="H0583FA69BCE54C37A402CF72C9637DCD"><enum>(B)</enum><header>Contents of study</header><text display-inline="yes-display-inline">In conducting the study under subparagraph (A), the Comptroller General shall examine the following: </text><clause id="HFA7A671D50604CDDBE5553D6AFD183B4"><enum>(i)</enum><text display-inline="yes-display-inline">The indications for each drug or biological product that—</text><subclause id="H5638A47A0A2C40FBA59AC0A7298DCE62"><enum>(I)</enum><text>is the subject of a rare pediatric disease product application (as defined in section 529 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/360ff">21 U.S.C. 360ff</external-xref>)) for which a priority review voucher was awarded; and</text></subclause><subclause id="HF4B3A58C1CEA4A41B1A36D800E0D70A0"><enum>(II)</enum><text>was approved under section 505 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/42/355">42 U.S.C. 355</external-xref>) or licensed under section 351 of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/262">42 U.S.C. 262</external-xref>).</text></subclause></clause><clause id="H1F8D39A959794315A8CD40FF53DC8128"><enum>(ii)</enum><text>Whether, and to what extent, an unmet need related to the treatment or prevention of a rare pediatric disease was met through the approval or licensure of such a drug or biological product. </text></clause><clause id="H0409B0B76209486696CD9D43294C74A0"><enum>(iii)</enum><text display-inline="yes-display-inline">The size of the company to which a priority review voucher was awarded under section 529 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/360ff">21 U.S.C. 360ff</external-xref>) for such a drug or biological product.</text></clause><clause id="H32995DA02D63476091C0785F57ACE1D8"><enum>(iv)</enum><text>The value of such priority review voucher if transferred. </text></clause><clause id="H759EA4627D9040E3B513E0DE8C61E48D"><enum>(v)</enum><text>Identification of each drug for which a priority review voucher awarded under such section 529 was used. </text></clause><clause id="H465B042237A844A387C23AA5040D99FA"><enum>(vi)</enum><text>The size of the company using each priority review voucher awarded under such section 529.</text></clause><clause id="HAB229A257D8549909A4D1CF09D59E56A"><enum>(vii)</enum><text display-inline="yes-display-inline">The length of the period of time between the date on which a priority review voucher was awarded under such section 529 and the date on which it was used. </text></clause><clause id="H4FA5819A95794F77A3B673DBD329EC67"><enum>(viii)</enum><text display-inline="yes-display-inline">Whether, and to what extent, an unmet need related to the treatment or prevention of a rare pediatric disease was met through the approval under section 505 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/42/355">42 U.S.C. 355</external-xref>) or licensure under section 351 of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/262">42 U.S.C. 262</external-xref>) of a drug for which a priority review voucher was used.</text></clause><clause id="HB16C3DBDC8744CA483A71282CE669744"><enum>(ix)</enum><text display-inline="yes-display-inline">Whether, and to what extent, companies were motivated by the availability of priority review vouchers under section 529 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/360ff">21 U.S.C. 360ff</external-xref>) to attempt to develop a drug for a rare pediatric disease.</text></clause><clause id="H0F3B6063D9244AD5826F67393B47E341"><enum>(x)</enum><text>Whether, and to what extent, pediatric review vouchers awarded under such section were successful in stimulating development and expedited patient access to drug products for treatment or prevention of a rare pediatric disease that wouldn’t otherwise take place without the incentive provided by such vouchers.</text></clause><clause id="H86B013D1C8B4496AB67024AA12AD1F85"><enum>(xi)</enum><text>The impact of such priority review vouchers on the workload, review process, and public health prioritization efforts of the Food and Drug Administration.</text></clause><clause id="H4DE65F8E95764670A9F2F43D7745FBE8"><enum>(xii)</enum><text>Any other incentives in Federal law that exist for companies developing drugs or biological products described in clause (i).</text></clause></subparagraph></paragraph><paragraph id="H96252A31CAA8457F979834C4FF7A9831"><enum>(2)</enum><header>Report on findings</header><text display-inline="yes-display-inline">Not later than 5 years after the date of the enactment of this Act, the Comptroller General of the United States shall submit to the Committee on Energy and Commerce of the House of Representatives and the Committee on Health, Education, Labor, and Pensions of the Senate a report containing the findings of the study conducted under paragraph (1).</text></paragraph></subsection></section></legis-body></bill> 

